Dr. Giuseppe Lombardi is a medical oncologist who earned his degree and specialization in Medical Oncology with honors, as well as a PhD in Oncology and Surgical Oncology (2014, thesis on glioma tumor biomarkers), all from the University of Padua. Passionate about brain tumor research—both clinical and laboratory—he completed international fellowships at leading centers such as Memorial Sloan Kettering Cancer Center (New York) and Pitié-Salpêtrière Hospital (Paris). He has authored over 200 international peer-reviewed publications and holds an H-index of 37 (Scopus, September 2025). Dr. Lombardi leads clinical trials on brain tumor treatments, including coordination of the REGOMA study, which led to the inclusion of regorafenib in the U.S. NCCN guidelines for glioblastoma. He also coordinates Padua’s inter-regional CNS tumor multidisciplinary group. A member of EORTC, EANO, and the AINO Board, he currently serves as Scientific Secretary for the Italian Association of Medical Oncology’s “Brain Tumor Guidelines.”